Correlation between Decorin and Oral Squamous Cell Carcinoma

doi:10.13701/j.cnki.kqyxyj.2020.05.009

Abstract

Abstract: Objective: To investigate the expression and significance of Decorin (DCN) in oral squamous cell carcinoma (OSCC), and the possible mechanism by which DCN affects the development of OSCC. Methods: The expressions of the DCN, epidermal growth factor receptor (EGFR), oncogene C-Myc, and cyclin dependent kinase inhibitor (P21) in OSCC tissues and normal gingiva tissues were detected by immunohistochemistry. After being transfected with DCN plasmid, the expressions of EGFR, C-Myc, and P21 in HSC-3 cells were detected by Real time PCR and Western blot. Results: With the decreasing of differentiation degree of OSCC, the positive expressions of DCN and P21 proteins were decreased gradually, while the EGFR and C-Myc proteins were increased gradually (P<0.05). Compared with HK group and control group, the mRNA and protein levels of EGFR and C-Myc in transfection group were decreased, while the mRNA and protein level of P21 was increased (P<0.05). Conclusion: DCN is related to the occurrence and development of OSCC, which might reach the goal by regulating the expressions of EGFR, C-Myc, and P21.

Key words: squamous cell carcinoma, DSPG-Ⅱ, epidermal growth factor receptor, C-myc proteins, cyclin kinase inhibitor p21

LAI Yongxian, NIE Minhai, CHEN Xiao, LIU Xuqian. Correlation between Decorin and Oral Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2020, 36(5): 437-442.

References

[1] 王倩,侯大为.口腔鳞状细胞癌发病及转移机制研究进展[J].口腔医学研究,2018,34(11):1164-1167.
[2] 于世凤. 口腔组织病理学[M] . 北京:人民卫生出版社,2019:380-382.
[3] Zhang W, Ge Y, Cheng Q, et al. DCN is a pivotal effector in the extracellular matrix and tumour microenvironment[J]. Oncotarget, 2018, 9(4):5480-5491.
[4] Theocharis AD, Karamanos NK. Proteoglycans remodeling in cancer: Underlying molecular mechanisms[J]. Matrix Biol, 2019, 75-76:220-259.
[5] Han YH, Abdul Hamid MR, Telisinghe PU, et al. Overexpression of EGFR protein in Bruneian lung cancer patients[J]. Asian Pac J Cancer Prev, 2015, 16(1):233-237.
[6] Canueto J, Cardenoso E, Garcia JL, et al. EGFR expression is associated with poor outcome in cutaneous squamous cell carcinoma[J]. Br J Dermatol, 2017, 176:1279-1287.
[7] Nishimura Y, Ezawa R, Ishii J, et al. Affibody-displaying bio-nanocapsules effective in EGFR, typical biomarker, expressed in various cancer cells[J]. Bioorg Med Chem Lett, 2017, 27(2):336-341.
[8] Huang SF, Chien HT, Chuang WY, et al. Epidermal growth factor receptor intron-1 CA repeat polymorphism on protein expression and clinical outcome in Taiwanese oral squamous cell carcinoma[J]. Sci Rep, 2017, 7(1):4963.
[9] Mundo L, Ambrosio MR, Raimondi F, et al. Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases[J]. Blood Cancer J, 2019, 9(12):91.
[10] Mei Y, Wu M. Noncoding RNAs regulating p53 and c-Myc signaling[J]. Adv Exp Med Biol, 2016, 927:337-365.
[11] Wang Z, Wang Z, Yan J, et al. MicroRNA-1294 inhibited oral squamous cell carcinoma growth by targeting c-Myc[J]. Oncol Lett, 2018, 16(2):2243-2250.
[12] Georgakilas AG, Martin OA, Bonner WM. p21: A two-faced genome guardian[J]. Trends Mol Med, 2017,23(4):310-319.
[13] Tran TQ, Lowman XH, Reid MA, et al. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction[J]. Oncogene, 2017,36(14):1991-2001.
[14] De Vicente JC, Pena I, Rodrigo JP, et al. Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma[J]. Head Neck, 2017, 39(9):1876-1887.
[15] Chen X, Gu W, Wang Q, et al. C-myc and BCL-2 mediate YAP-regulated tumorigenesis in OSCC[J]. Oncotarget, 2018, 9(1):668-679.
[16] 陈蔚华,裴婧,贾云香.EGFR、MTDH、ERCC1在口腔特殊亚型的鳞状细胞癌中的表达及临床意义[J]. 口腔医学研究, 2018, 34(6):623-626.
[17] Wang J, Li M, Chen D, et al. Expression of C-myc and β-catenin and their correlation in triple negative breast cancer[J]. Minerva Medica, 2017, 108(6):513-517.
[18] Singh K, Dong Q, Timirishanmugam PS, et al. Tetrandrine inhibits deregulated cell cycle in pancreatic cancer cells: Differential regulation of p21 Cip1/Waf1, p27 Kip1, and cyclin D1[J]. Cancer Lett, 2018, 425:164-173.
[19] Morrione A, Neill T, Iozzo RV. Dichotomy of decorin activity on the insulin-like growth factor-I system[J]. FEBS J, 2013, 280(10):2138-2149.